LOCOID
LOE ApproachingNDATOPICALLOTION
Approved
May 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOCOID is a topical lotion approved by the FDA in May 2007 for dermatological use. The generic name and mechanism of action are not specified in available data, limiting insight into its therapeutic target. It is manufactured by Bausch + Lomb and represents a mature NDA product in the topical anti-inflammatory or corticosteroid class.
LOE Approaching
Product is nearing loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and shift toward cost management and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for LOCOID-specific roles, typical of a declining-lifecycle product. Career advancement on this product is limited; professionals should expect focus on cost containment, generic transition support, and potential reassignment to growth-stage portfolios.
Brand ManagerCommercial Manager
Worked on LOCOID at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.